Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.25.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three months ended September 30, 

Nine Months Ended September 30, 

($ in thousands)

    

2025

    

2024

    

2025

    

2024

Emrosi

$

4,883

$

$

9,748

$

Qbrexza

7,361

7,583

19,470

19,435

Accutane

2,769

3,996

9,818

15,534

Vyne acquisition products (Amzeeq & Zilxi)

1,311

2,100

3,973

4,703

Other / legacy product revenue

701

950

2,164

2,842

Revenue – related party

 

 

 

 

41

Other revenue

606

2,010

 

Total net revenue

$

17,631

$

14,629

$

47,183

$

42,555